Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.

MLA

Magbanua, Mark Jesus M., et al. “Clinical Significance and Biology of Circulating Tumor DNA in High-Risk Early-Stage HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.” Cancer Cell, vol. 41, no. 6, June 2023, p. 1091. EBSCOhost, https://doi.org/10.1016/j.ccell.2023.04.008.

APA

Magbanua, M. J. M., Brown Swigart, L., Ahmed, Z., Sayaman, R. W., Renner, D., Kalashnikova, E., Hirst, G. L., Yau, C., Wolf, D. M., Li, W., Delson, A. L., Asare, S., Liu, M. C., Albain, K., Chien, A. J., Forero-Torres, A., Isaacs, C., Nanda, R., Tripathy, D., & Rodriguez, A. (2023). Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell, 41(6), 1091. https://doi.org/10.1016/j.ccell.2023.04.008

Chicago

Magbanua, Mark Jesus M., Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova, Gillian L. Hirst, et al. 2023. “Clinical Significance and Biology of Circulating Tumor DNA in High-Risk Early-Stage HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.” Cancer Cell 41 (6): 1091. doi:10.1016/j.ccell.2023.04.008.